SAGE-718 ( DrugBank: Sage )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2
8	ハンチントン病	4

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05318937 (ClinicalTrials.gov)	July 6, 2022	1/4/2022	A Study to Evaluate the Effects of SAGE-718in Participants With Parkinson's Disease Cognitive Impair ...	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718in Parkinson ...	Parkinson Disease;Cognitive Dysfunction	Drug: SAGE-718;Drug: SAGE-718-matching placebo	Sage Therapeutics	NULL	Recruiting	50 Years	75 Years	All	76	Phase 2	United States
2	NCT04476017 (ClinicalTrials.gov)	September 11, 2020	15/7/2020	A Study to Evaluate the Safety and Tolerability of SAGE-718in Participants With Parkinson's Disease ...	An Open-Label Evaluation of the Safety and Tolerability of SAGE-718in Participants With Parkinson's ...	Parkinson Disease;Cognitive Dysfunction	Drug: SAGE-718	Sage Therapeutics	NULL	Completed	50 Years	75 Years	All	18	Phase 2	United States

First Previous1Next Last

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05655520 (ClinicalTrials.gov)	December 14, 2022	9/12/2022	A Study to Evaluate the Safety and Tolerability of SAGE-718in Participants With Huntington's Disease ...	A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of ...	Huntington Disease	Drug: SAGE-718	Sage Therapeutics	NULL	Recruiting	25 Years	65 Years	All	300	Phase 3	United States
2	NCT05358821 (ClinicalTrials.gov)	June 22, 2022	27/4/2022	A Study to Evaluate the Effect of SAGE-718on Functioning Capacity in Participants With Huntington's ...	A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Stud ...	Huntington Disease	Drug: SAGE-718;Drug: Placebo	Sage Therapeutics	NULL	Recruiting	25 Years	65 Years	All	80	Phase 2	United States
3	NCT05107128 (ClinicalTrials.gov)	February 10, 2022	25/10/2021	A Study to Evaluate the Effect of SAGE-718on Cognitive Function in Participants With Huntington's Di ...	A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718on Cognitive ...	Huntington's Disease	Drug: SAGE-718;Drug: Placebo	Sage Therapeutics	NULL	Recruiting	25 Years	65 Years	All	178	Phase 2	United States;Australia;Canada;United Kingdom
4	NCT03787758 (ClinicalTrials.gov)	February 28, 2019	17/12/2018	A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718Oral Solution in Patients ...	A Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, ...	Huntington Disease	Drug: SAGE-718	Sage Therapeutics	NULL	Completed	18 Years	70 Years	All	6	Phase 1	United States

First Previous1Next Last

先頭へ